RA Capital Management led a $90m round in Bambusa Therapeutics.

RA Capital Management, a private equity firm, led a $90m round in Bambusa Therapeutics, a biotechnology company developing bispecific antibodies for immunological and inflammatory disorders, with participation from Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Managemen. "At Bambusa, we have assembled a dynamic team of emerging biotech entrepreneurs driven by speed, agility, and scientific excellence. We are grateful for the trust our new and existing investors have placed in us as we rapidly advance our bispecific antibody pipeline into the clinic. This financing is a testament to our vision and execution, and we are eager to continue building momentum toward delivering transformative therapies to patients in need," Shanshan Xu, Bambusa Therapeutics CEO and Founder.